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The Environment and Healthcare-Acquired 
Infections: Why Accurate Reporting and 
Evaluation of Biological Plausibility 
Are Important 
To the Editor—We read with interest the article by Salgado 
and colleagues,1 describing a randomized clinical trial in-
volving 614 patients in intensive care unit (ICU) rooms with 
or without the addition of copper alloy surfaces on 6 fre-
quently touched items in the near-patient environment. The 
2 primary outcomes were incidence of (a) any healthcare-
associated infection (HAI) and (b) any ICU-acquired colo-
nization with methicillin-resistant Staphylococcus aureus 
(MRSA) or vancomycin-resistant enterococci (VRE) detected 
from surveillance swab samples or clinical cultures. The au-
thors concluded that placing copper surfaces into ICU rooms 
reduced the risk of HAI by more than 50%. Although this 
trial represents a substantial amount of laudable work, we 
have concerns with 3 important issues: (1) the approach taken 
to reporting study outcomes; (2) lack of information con-
cerning the determination of study end points; and (3) a 
failure to evaluate the biological plausibility of the findings. 
First, the authors created a complex system of 2 single and 
4 composite outcomes that included patients who had (a) 
any episode of HAI; (b) any episode of MRSA or VRE col-
onization; (c) both HAI and colonization (ie, only patients 
who had both events); (d) HAI and/or colonization (ie, pa-
tients with either HAI or colonization, meaning any event); 
(e) HAI only without colonization (ie, patients with HAI 
minus those who had both HAI and colonization); and (f) 
colonization only without HAI (ie, patients with colonization 
minus those who had both HAI and colonization). Combined 
data for both trial arms were available for all outcomes (a)-
(f), but separate data for each trial arm were reported only 
for outcomes (d)-(f), not for (a)-(c). For (d) and (e), there 
was a significant reduction of events in favor of copper-treated 
rooms, and for (f), there was a nonsignificant reduction. The 
statistical significance of composite outcomes (d) and (e) 
apparently provided the basis for the conclusions. However, 
we believe that rates stratified by treatment arm for (a) any 
HAI and (b) any colonization would have been biologically 
and clinically most relevant. Combining the 2 end points 
(under d) may not be informative, because the causal path-
ways for both are biologically different. In addition, outcomes 
(e) and (f) are unnecessarily complex and appear artificially 
constructed. 
We extracted the missing numbers for the primary end 
points (a) and (b) from the article. For both noncomposite 
primary outcomes (a) and (b), the differences were not sta-
tistically significant (by x2 and Fisher exact tests). A com-
pilation of reported (in the article by Salgado et al1) and 
extracted (not reported) outcomes is shown in Table 1. This 
has 2 implications. Nonreporting of 2 prespecified primary 
outcomes for each trial arm constitutes a case of selective 
reporting,2 and the conclusion that copper-equipped rooms 
reduced the rate of any new HAIs (corresponding to primary 
outcome [a]) is now questionable. 
Second, there remains uncertainty over end point deter-
mination in this clinical trial with high interobserver vari-
ability and disagreement in outcome ascertainment and val-
idation (K statistics, 0.52). How were new MRSA or VRE 
acquisitions detected and defined? This is obviously impor-
tant for the overall outcome, especially because one site was 
not performing admission screening for VRE, and exclusion 
of MRSA carriage depended solely on nasal swab samples 
across all sites. How was colonization defined, as opposed to 
infection, and what were the specific acquisition rates of 
MRSA and VRE? The most striking HAI reduction was ob-
served for bloodstream infection (BSI) rates. Were these ep-
isodes related to primary or secondary BSI? What were the 
central venous catheter (CVC)-related BSI rates expressed per 
1,000 CVC-days and stratified by treatment arm? Finally, 
there are insufficient data on compliance with hand hygiene 
before patient contact, particularly any differences among 
staff dealing with patients in both types of study room.3 
Third, we have concerns about the biological plausibility 
of the main findings. The major source of healthcare-asso-
ciated pathogens is thought to be the patient's endogenous 
flora, but an estimated 20% of pathogens are acquired via 
other transmission routes, such as the environment, and 
20%-40% is attributed to cross-infection via the contami-
nated hands of healthcare personnel.4"7 Thus, it remains un-
clear how copper-treated surfaces could have had such a sub-
stantial effect on reducing HAIs, taking into account the fact 
that only 10% of ICU surfaces were copper-equipped and 
that 13% of control patients were exposed to copper objects. 
If there was a greater than 50% reduction of HAIs as a result 
of copper surfaces, this would mean that endogenous origin, 
exogenous transmission through direct contact, and trans-
mission from all other (noncopper) surfaces were implicated 
in only a minority of HAIs. This is not consistent with the 
known pathophysiology of ICU-acquired HAIs, including 
primary and secondary BSIs.8 
Anyone doing research can retrieve observations that con-
front conventional wisdom and challenge existing evidence.9 
The essence of research is venturing into the unknown. Cer-
tainly, the possibility that there was an association between 
overall HAI risk and higher microbial levels from hand-touch 
sites, whether copper coated or not, was of interest. However, 
we feel that this study (apparently not registered a priori on 
an open-access trial registration site) provides more questions 
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TABLE i. Primary and Composite Outcomes for Patients in Rooms with and without Copper-Coated Surfaces 
No. of patients, by type of room P 
Without 
Copper-coated surfaces copper-coated surfaces Total 
Outcome3 (n = 294) (n = 320) (n = 614) x2 test8 Fisher exact test 
Any HAI event (a) 17f 29f 46 .12 .13 
Any MRSA or VRE colonization event (b) l l f 15f 26 .56 .69 
Both HAI and colonization (c)b 7f 3f 10 .16 .21 
HAI and/or colonization (d)c 21 41 62 .020 .023 
HAI only (e)d 10 26 36 .013 .015 
Colonization only (f)e 4 12 16 .063 .077 
NOTE. HAI, healthcare-acquired infection; MRSA, methiciOin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci. 
* Letters in parentheses correspond to those in the text. 
b
 Both events occurring in the same patient. 
c
 Either HAI or colonization or both (ie, any event). 
d
 No. of patients with HAI minus those who had both HAI and colonization. 
' No. of patients with colonization minus those who had both HAI and colonization. 
' These numbers were not provided in the original article by Salgado et al1 and instead were extracted and calculated from the other 
reported data. 
8
 Without Yates correction. 
than answers, and we would appeal for additional work on 
linking antimicrobial surfaces with HAI transmission in ICUs. 
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Reply to Harbarth et al 
To the Editor—We thank Harbarth et al1 for their character-
ization of our work as laudable, but offer the following per-
spective on their critique of the design and interpretation of 
data from our study.2 It is firmly established that hospital-
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